Market Place
Sourcing Support
Cocrystal Pharma Reports Q3 2024 Results & Antiviral Updates
13 Nov 2024 //
GLOBENEWSWIRE
Cocrystal Co-CEOs Discuss Antiviral Drug Approach for Flu & COVID
31 Oct 2024 //
GLOBENEWSWIRE
Cocrystal Pharma Advances CDI-988 Into Phase 1 Dose Cohorts
26 Sep 2024 //
GLOBENEWSWIRE
Cocrystal Pharma To Present At Two Upcoming Investment Conferences
19 Aug 2024 //
GLOBENEWSWIRE
CoCrystal Pharma To Present At August 20th Virtual Investor Summit Microcap
15 Aug 2024 //
ACCESSWIRE
Cocrystal Pharma Reports Q2 2024 Financial Results And Antiviral Program Updates
14 Aug 2024 //
GLOBENEWSWIRE
Cocrystal Pharma Reports Positive Phase 1 Results For Antiviral CDI-988
18 Jul 2024 //
GLOBENEWSWIRE
New Antiviral In Phase 2a Trial For Influenza A May Work Against H5N1 Avian Flu
20 Jun 2024 //
GLOBENEWSWIRE
Cocrystal Pharma Reports Q1 2024 Results, Antiviral Program Updates
13 May 2024 //
GLOBENEWSWIRE
Cocrystal: Phase 2a Enrollment Complete For CC-42344 In Flu
01 May 2024 //
GLOBENEWSWIRE
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates
28 Mar 2024 //
GLOBENEWSWIRE
Cocrystal Receives Pre-IND Responses FDA on Oral CC-42344 for Influenza A
19 Mar 2024 //
GLOBENEWSWIRE
Cocrystal Provides an Update on the Clinical Development of its Novel Candidates
04 Jan 2024 //
GLOBENEWSWIRE
Cocrystal Announces First-Patient-In for Phase 2a Study Evaluating CC-42344
06 Dec 2023 //
GLOBENEWSWIRE
Cocrystal Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344
29 Nov 2023 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
27 Nov 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Cocrystal Pharma to Discuss Progress with Oral Influenza A Antiviral CC-42344
09 Nov 2023 //
GLOBENEWSWIRE
Cocrystal Receives MHRA Authorization to Initiate Phase 2a Trial with CC-42344
31 Oct 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988
28 Sep 2023 //
GLOBENEWSWIRE
Cocrystal Pharma to Participate in H.C. Wainwright Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
08 Aug 2023 //
GLOBENEWSWIRE
Cocrystal receives approval from HREC for Phase I trial of Covid-19 therapy
01 Jun 2023 //
CLINICAL TRIALS ARENA
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study
31 May 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Reports 1Q 2023 FYR Results and Provides Updates
15 May 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Presents New Data from its CC-42344 pH 1 Influenza A Study
04 May 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its BOD
24 Apr 2023 //
GLOBENEWSWIRE
Cocrystal Completes $4 Million Private Placement Priced At-the-Market
10 Apr 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Reports 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio
22 Mar 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Announces Participation in Virtual Investor Events
26 Jan 2023 //
GLOBENEWSWIRE
Cocrystal Pharma Reports SafetyResults from PI Study with Antiviral CC-42344
19 Dec 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment
01 Dec 2022 //
GLOBENEWSWIRE
Cocrystal Announces Favorable Safety Data from the Ph1 Study with Oral CC-42344
17 Nov 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Reports 3Q 2022 Financial Results and Provides Updates
14 Nov 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Granted European Patent Covering Oral Antiviral CC-42344
01 Nov 2022 //
GLOBENEWSWIRE
Enrollment Completed in PI Influenza A Study
26 Oct 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at the LD Micro Main Event XV
19 Oct 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data a
13 Oct 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at Dawson James Securities 2022 Small Cap Growth
05 Oct 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
03 Oct 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Participate in the H.C. WainwrightGIC
06 Sep 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Engages CRO in PIIa Influenza A Trial of CC-42344
08 Aug 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A
14 Jul 2022 //
GLOBENEWSWIRE
Cocrystal Pharma, NIAID Expand Collaboration for COVID-19 Protease Inhibitors
01 Jun 2022 //
GLOBENEWSWIRE
Cocrystal Collaborates with the National Institute of Allergy and ID
21 Apr 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at Life Science Innovation Northwest 2022
19 Apr 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference
14 Apr 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Reports 2021 Financial Results on Development and Milestones
23 Mar 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Participate in Maxim Group 2022 Virtual Growth Conference
22 Mar 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Initiates Enrollment in P 1 Influenza A Study with CC-42344
10 Mar 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Participate in Upcoming Investment Conferences
03 Mar 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Selects Antiviral Drug Candidates for COVID Oral Drug Program
27 Jan 2022 //
GLOBENEWSWIRE
Cocrystal Pharma Bags FDA Guidance to Advance Clinical Development of CDI-45205
06 Jan 2022 //
GLOBENEWSWIRE
Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference
04 Jan 2022 //
GLOBENEWSWIRE
Cocrystal Pharma’s COVID-19 Oral &Intranasal/Pulmonary Protease InhibExhibit
22 Dec 2021 //
GLOBENEWSWIRE
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs
02 Dec 2021 //
GLOBENEWSWIRE
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Pan-viral Activity
08 Nov 2021 //
GLOBENEWSWIRE
